Dumping drug discovery makes Tysabri-rich Elan tastier takeover target
This article was originally published in Scrip
Executive Summary
Elan could look like an attractive takeover target for a big pharma or biotech company looking for an uncomplicated profit boost, now that it has announced plans to split out its profitable Tysabri and later-stage assets from its early-stage drug discovery business and cut its workforce down from 380 to around 170-190 across the two firms. The front-runner for potential bids would indeed probably be its Tysabri partner Biogen Idec.
You may also be interested in...
Gaming Whiz Brings AI Smarts To Drug Discovery
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
Need a specific report? 1000+ reports available
Buy Reports